Seventy-first Meeting of the **Obstetrics and Gynecology Devices Panel**

March 28, 2006 Gaithersburg Hilton, Gaithersburg, MD

General Topic Discussion – Pivotal Studies to Evaluate New Treatment Modalities for Symptomatic Uterine Fibroids Roster

Kenneth Noller, M.D., Panel Chair

Department of Obstetrics & Gynecology, Tufts University Medical School, Boston, MA

Diana Romero, Ph.D., Consumer Representative

Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University, New York, NY

Elisabeth George, Industry Representative

Phillips Medical Systems, Newton, MA

Paula Hillard, M.D., Voting Member

Department of Obstetrics and Gynecology and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

Hugh Miller, M.D., Voting Member

Department of Obstetrics and Gynecology, Arizona Health Science Center, Tucson, AZ

Jonathan Weeks, M.D., Voting Member

Maternal-Fetal Medicine Center, Norton Suburban Hospital, Louisville, KY

Marcelle I. Cedars, M.D., Voting Member

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA

Howard Sharp, M.D., **Voting Member**

General Division of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT

Joseph Sanfilippo, M.D., M.B.A., Voting Member

Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, PA

Scott Emerson, M.D., Ph.D., Consultant¹

Department of Biostatistics, University of Washington, Seattle, WA

Nasser Chegini, Ph.D., **Consultant** Department of Obstetrics and Gynecology, University of Florida, Gainesville, FL

Nancy Sharts-Hopko, R.N., Ph.D., **Consultant** College of Nursing, Villanova University, Villanova, PA

Gerald Shirk, M.D., **Consultant** OB-GYN Associates, PC, Cedar Rapids, IA

Russell Snyder, M.D., **Consultant**Department of Obstetrics and Gynecology, The University of Texas Medical Branch,
Galveston, TX

¹Dr. Emerson, a voting member on CDER's Reproductive Drugs Panel, will be serving as a consultant to our panel today.